Pen-G plant fire disruption
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
AUROPHARMA / Q4-FY25 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Potential US tariffs on pharmaceutical imports
Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
Muted injectable growth in FY26 due to Eugia-3 remediation
Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
Revlimid revenue decline in FY26
Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.